AGENUS INC (AGEN)
US00847G8042 - Common Stock
Agenus (AGEN) Q1 2024 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2024.
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q1 2024
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Agenus Reports First Quarter 2024 Results
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
Up 40%: Is This Red-Hot Growth Stock Still a Buy?
This small-cap biotech stock is surging. Time to buy?
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Commit To Purchase Agenus At $1, Earn 2607.1% Annualized Using Options
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Agenus Announces Reverse Stock Split of Common Stock
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks.
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.
Agenus (AGEN) Q4 2023 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2023.
Agenus Reports Fourth Quarter and Full Year 2023 Results
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
Agenus to Participate in Leerink Partners Global Biopharma Conference
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
The company hopes to engineer a 1-for-20 reverse stock split.
Ginkgo stock gains after $31M contract win with Agenus
SaponiQx, a unit of Agenus (AGEN), and Ginkgo Bioworks (DNA) have won a multi-year contract worth up to $31M to sudy vaccine adjuvants. Read more here.
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
/PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program...
Moderna RSV vaccine lags rival shots in long-term efficacy
TD Cowen argues that Moderna's (MRNA) upcoming mRNA-based RSV vaccine has a faster decline in efficacy compared to rival shots from Pfizer (PFE) and GSK (GSK). Read more here.
GSK RSV shot under FDA priority review for label expansion
GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, is under priority review by the FDA for a label expansion to age group 50-59. Read more here.